Biocytogen is committed to developing innovative antibody drugs that meet the needs of patients, focusing on oncology, autoimmune, inflammatory, metabolic and and other diseases. Taking full advantage of its unique advantage in innovative drug development the company now has more than 10 R & D pipelines including monoclonal antibodies, bispecific antibodies, ADC drugs and so on. With the support of a strong clinical development team and abundant clinical resources, the company will push forward the product pipeline at full speed to accelerate the clinical trial process.
Oncology
Molecular Format:
Monoclonal antibody
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Molecular Format:
Monoclonal Antibody
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Molecular Format:
Monoclonal Antibody
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Molecular Format:
Monoclonal antibody
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Molecular Format:
Bispecific antibody
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Molecular Format:
Bispecific antibody
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Molecular Format:
Bispecific antibody
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Molecular Format:
Bispecific ADC
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Molecular Format:
Bispecific ADC
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Molecular Format:
Monoclonal Antibody
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Molecular Format:
Monoclonal Antibody
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Molecular Format:
Monoclonal Antibody
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Molecular Format:
Monoclonal Antibody
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Molecular Format:
Monoclonal Antibody
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Molecular Format:
Monoclonal Antibody
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Infectious Diseases
Molecular Format:
Monoclonal antibody
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA